TABLE 3

Longitudinal Random-Effects Models (Base Models) for Lung Function From Ages 11–26 Years and LRIs During the First 3 Years of Life

LRIsFEV1, mLFVC, mLFEV1:FVC Ratio, %FEF25–75, mL/sFEF25–75:FVC Ratio, %
B (SE)PB (SE)PB (SE)PB (SE)PB (SE)P
Prealbuterol lung function at ages 11–26 years
 No LRIRefRefRefRefRef
 Pneumonia−117.22 (54.94).03346.34 (64.12).470−3.92 (0.93)<.001−417.77 (114.02)<.001−12.38 (3.17)<.001
 Other LRIs−62.79 (27.87).024−21.90 (32.53).501−1.12 (0.47).018−160.14 (57.79).006−4.11 (1.60).010
Postalbuterol lung function at ages 11–26 years
 No LRIRefRefRefRefRef
 Pneumonia−67.23 (53.68).21055.83 (64.80).389−2.54 (0.79).001−348.36 (111.54).002−9.49 (3.14).002
 Other LRIs−40.83 (27.28).134−18.18 (32.92).581−0.64 (0.40).111−125.19 (56.66).027−3.20 (1.59).044
  • All base models included age, gender, height, race/ethnicity, and LRIs. The number of observations for the prealbuterol FEV1 model was 1676; the number of individuals included in the analysis was 646, with an average number of observations per individual of 2.6. B, model coefficient; Ref, reference group in the model.